Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura

Transfus Med. 2013 Feb;23(1):66-68. doi: 10.1111/j.1365-3148.2012.01197.x. Epub 2012 Oct 29.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / blood
  • ADAM Proteins / immunology
  • ADAMTS13 Protein
  • Antiviral Agents / therapeutic use*
  • Autoantibodies / blood
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / complications*
  • Autoimmune Diseases / immunology
  • Biopsy
  • Female
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Hepatomegaly / etiology
  • Hepatomegaly / pathology
  • Humans
  • Interferon-alpha / therapeutic use*
  • Middle Aged
  • Polyethylene Glycols / therapeutic use*
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / complications*
  • Purpura, Thrombotic Thrombocytopenic / immunology
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Ribavirin / therapeutic use
  • Splenomegaly / etiology
  • Splenomegaly / pathology
  • von Willebrand Factor / analysis

Substances

  • Antiviral Agents
  • Autoantibodies
  • Interferon-alpha
  • Recombinant Proteins
  • von Willebrand Factor
  • Polyethylene Glycols
  • Ribavirin
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
  • peginterferon alfa-2a